GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Other Net Income (Loss)

Incanthera (AQSE:INC) Other Net Income (Loss) : £0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Other Net Income (Loss)?

Incanthera's Other Net Income (Loss) for the six months ended in Sep. 2023 was £0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 was £0.00 Mil.

Incanthera's quarterly Other Net Income (Loss) increased from Sep. 2022 (£0.00 Mil) to Mar. 2023 (£0.00 Mil) but then declined from Mar. 2023 (£0.00 Mil) to Sep. 2023 (£0.00 Mil).


Incanthera Other Net Income (Loss) Historical Data

The historical data trend for Incanthera's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Other Net Income (Loss) Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Other Net Income (Loss)
- - - -

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Other Net Income (Loss) Get a 7-Day Free Trial - - - - -

Incanthera Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incanthera Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Incanthera's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera Headlines